A cost and access comparison of oral micronized progesterone (Prometrium and generics) and vaginal estradiol for women's hormone therapy, including insurance coverage patterns, generic pricing ranges, and where the two drugs are not interchangeable.
A clinical comparison of the side-effect profiles of oral micronized progesterone (Prometrium) and vaginal estradiol, including drowsiness, bleeding patterns, systemic exposure, and cardiovascular safety data from the PEPI trial and Cochrane reviews.
Meta-analysis data show 150+ min/week aerobic plus 2 resistance sessions resolves metabolic syndrome criteria in 12 to 16 weeks, independent of weight loss.
Metabolic syndrome and mental health disorders share biological pathways involving inflammation, cortisol dysregulation, and insulin resistance. Learn how depression, anxiety, schizophrenia, and bipolar disorder intersect with cardiometabolic risk.
First-line is lifestyle change (7-10% weight loss, 150 min/week exercise, Mediterranean/DASH diet). Second-line adds drugs; third-line is bariatric surgery.
Obesity (BMI ≥30) raises risk for 200+ conditions, most notably type 2 diabetes, heart disease, sleep apnea, MASLD, and osteoarthritis. See how they overlap.
Evidence-based OSA treatment algorithm organized by line of therapy, from CPAP and oral appliances to tirzepatide and surgical options, with AHI-based staging and trial data.
Evidence-based nutrition and lifestyle protocols for PCOS (Polycystic Ovary Syndrome), including dietary patterns, exercise recommendations, supplements, and GLP-1 therapies backed by clinical trials and major society guidelines.
A clinical review of the latest perimenopause research, including neurokinin-3 receptor antagonists, novel biomarkers, combination HRT trials, and updated society guidelines shaping treatment in 2025 and beyond.
Your genes influence wound healing speed, pain sensitivity, clot risk, and drug metabolism after surgery. Learn which genetic variants matter most for post-surgical recovery and what to discuss with your surgeon.
Post-surgical recovery often triggers depression, anxiety, and cognitive changes. Learn how mental health conditions overlap with surgical healing, what the evidence says, and how clinicians can address both simultaneously.
A guide to the most promising prediabetes research, from GLP-1 receptor agonists and dual-incretin therapies to precision diagnostics and microbiome interventions. Includes key trials, timelines, and clinical implications.
Tendinopathy rarely occurs in isolation. Diabetes, obesity, thyroid dysfunction, cardiovascular disease, and certain medications all raise tendon injury risk. Learn the comorbid conditions linked to chronic tendinopathy and how they shape treatment.
A clinical review of the most promising emerging therapies, active clinical trials, and new diagnostic tools for tendinopathy, including PRP, BPC-157, stem cells, shockwave therapy, and novel biologics.
Dapagliflozin is cleared mainly by UGT1A9 glucuronidation to an inactive 3-O-glucuronide. CYP450 does little, so CYP-based drug interactions stay limited.
Evidence-based guide to metformin for gestational diabetes, including clinical trial data from MiG and other studies, safety profile, dosing, and how it compares to insulin therapy.
Find out if Anthem Blue Cross Blue Shield covers Jardiance (empagliflozin), what formulary tier it falls on, typical copay ranges, prior authorization requirements, and lower-cost alternatives.
Evidence-based review of turmeric and curcumin for weight loss, including clinical trial data on BMI, waist circumference, and body fat, plus dosing and safety guidance.
Learn how polycystic ovary syndrome (PCOS) is diagnosed, including the Rotterdam criteria, key signs and symptoms, blood tests, ultrasound findings, and what to expect during evaluation.
Glipizide is a sulfonylurea prescribed for type 2 diabetes. Learn how it works, standard dosing, side effects, hypoglycemia risk, and how it compares to newer agents like metformin and GLP-1 agonists.
Blood pressure often rises during menopause due to estrogen decline, vascular stiffness, and metabolic shifts. Learn evidence-based causes and relief strategies.
A clinical deep dive into the future of dulaglutide (Trulicity), including Eli Lilly's GLP-1 pipeline, next-generation agonists, oral formulations, and combination therapies in development.
A clinical review of dutasteride (Avodart) manufacturing, GSK production history, soft gelatin capsule supply challenges, generic market entry, and documented shortage events.
A guide to dutasteride's off-label applications beyond BPH, including androgenetic alopecia, hirsutism, and prostate cancer chemoprevention, with evidence grades and cited clinical trials.
Dutasteride (Avodart) is FDA Pregnancy Category X. This article covers teratogenic risk, blood donation restrictions, partner exposure precautions, lactation data, and clinical guidance for 5-alpha reductase inhibitor use near conception.
Evidence-based guide to tapering and discontinuing enclomiphene citrate safely, including timeline, monitoring labs, post-cessation testosterone recovery, and when to restart therapy.
How CYP2D6, CYP3A4, ESR1, and other gene variants influence enclomiphene citrate response, dosing, and side-effect risk in men with secondary hypogonadism.
Epitalon has no published price and no FDA approval. This page covers its compounding status, FDA's safety findings and the limited efficacy evidence.
A clinical review of epitalon tetrapeptide patent status, intellectual property history, regulatory pathway, and what the absence of FDA approval means for generic availability and patient access.
A clinician-grade overview of oral estradiol's regulatory approvals, prescribing frameworks, and market availability across the United States, European Union, Canada, and the United Kingdom.
Complete dosing guide for oral estradiol in young adults aged 18 to 29, covering indications, starting doses, titration, monitoring, and fertility considerations.
A clinician-grade review of estradiol transdermal patch safety signals, FDA boxed warnings, post-market surveillance data, and risk-mitigation strategies based on WHI and post-WHI evidence.
Evidence-based guide to amlodipine dosing in Black and African ancestry patients, including pharmacogenomic considerations, trial data from ALLHAT and ASCOT-BPLA, and clinical recommendations for optimizing blood pressure control.
Evidence-based guide to adjusting AndroGel (testosterone gel) dosing in South Asian men, covering pharmacogenomic factors, cardiovascular risk thresholds, and monitoring protocols specific to this population.
Evidence-based guide to AOD-9604 (HGH fragment 176-191) dosing considerations for Black and African ancestry patients, covering pharmacogenomics, metabolic differences, and clinical monitoring.
Clinical review of AOD-9604 (HGH fragment 176-191) safety considerations for Black and African ancestry patients, covering pharmacogenomics, dosing, metabolic context, and monitoring gaps.
BPC-157 pentadecapeptide lacks ethnicity-stratified human trial data. This article covers pharmacogenomic factors, G6PD considerations, renal risk, and monitoring guidance for Black / African ancestry patients considering BPC-157.
Evidence review of BPC-157 pentadecapeptide efficacy in South Asian populations, covering pharmacogenomic variability, dosing considerations, and documented gaps in ethnicity-stratified clinical data.
Evidence-based review of BPC-157 pentadecapeptide safety considerations for South Asian individuals, including pharmacogenomic factors, cardiovascular risk at lower BMI thresholds, and dosing guidance.
Evidence review of bremelanotide (Vyleesi) efficacy differences in Hispanic / Latino populations, covering RECONNECT trial subgroup data, MC4R pharmacogenomics, metabolic confounders, and practical dosing guidance.
Evidence-based review of bremelanotide (Vyleesi) efficacy in South Asian women, including MC4R pharmacogenomics, cardiovascular screening at lower BMI thresholds, and ethnicity-stratified trial gaps.
Evidence-based review of how bremelanotide (Vyleesi) safety, pharmacogenomics, and dosing considerations differ for South Asian women, including cardiovascular monitoring and melanocortin receptor variability.
How South Asian genetics, cardiovascular risk factors, and metabolic patterns affect tadalafil (Cialis) safety, dosing, and monitoring. Evidence-based guidance with pharmacogenomic context.
Evidence-based guide to CJC-1295 modified GRF dosing considerations for Black and African ancestry patients, including pharmacogenomic factors, GH axis variability, and clinical monitoring protocols.
Evidence-based review of CJC-1295 (modified GRF 1-29) safety considerations for South Asian populations, including pharmacogenomic variation, cardiovascular risk at lower BMI thresholds, and clinical monitoring adjustments.
Evidence-based guide to dulaglutide dosing considerations for Black and African ancestry patients, including REWIND subgroup data, pharmacogenomic factors, and cardiorenal context.
Evidence-based review of dulaglutide (Trulicity) efficacy differences in Black and African ancestry populations, including REWIND subgroup data, pharmacogenomic factors, and dosing considerations.
Evidence-based guide to dulaglutide (Trulicity) dosing considerations for Hispanic and Latino patients, covering pharmacogenomics, metabolic phenotypes, and clinical trial subgroup data.
Evidence-based guide to epitalon tetrapeptide dosing in East Asian patients, covering CYP polymorphism frequencies, BMI-based adjustments, peptide pharmacokinetics, and monitoring recommendations.
An evidence-based review of epitalon tetrapeptide efficacy data in Hispanic and Latino populations, covering pharmacogenomics, dosing considerations, diabetes-related phenotypes, and what clinicians should monitor.
The tablet label has no ancestry-based dose or efficacy difference. The WHI tested conjugated estrogens, not estradiol, and gene data are lab-only.
A cautious, evidence-boundary review of what is known and not yet established about oral estradiol pharmacokinetics, dosing, and safety in East Asian populations, including where pharmacogenomic and body-weight reasoning is extrapolated rather than directly trial-tested.
Evidence-based guidance on estradiol transdermal patch dosing in Black and African ancestry women, covering pharmacogenomics, cardiovascular considerations, and individualized HRT strategies.
Evidence-based guide to estradiol transdermal patch dosing in Hispanic and Latino women, covering pharmacogenomic variants, metabolic considerations, and clinical monitoring strategies.
Evidence-based guide to finasteride dosing in East Asian populations, covering pharmacogenomic differences, CYP enzyme variants, clinical trial data, and practical prescribing considerations.
Evidence-based review of how finasteride performs in Hispanic and Latino populations, including pharmacogenomic variants, dosing considerations, and efficacy data from clinical trials.
Published GHK-Cu human trials report no results by race, and they were small. FDA status of copper peptide products applies to every patient.
Evidence review of ipamorelin acetate efficacy differences in Black and African ancestry populations, covering pharmacogenomics, GH axis variability, GHSR polymorphisms, and race-stratified clinical data gaps.
Evidence-based guide to ipamorelin acetate dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, GH-axis variation, and practical dose-adjustment strategies.
Evidence-based guide to ipamorelin acetate dosing considerations for South Asian patients, covering pharmacogenomics, metabolic phenotype differences, body composition factors, and clinical monitoring protocols.